<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty patients (median age of 32 years; range, 6-61) with <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> received unmanipulated peripheral blood stem cell transplants from HLA-matched or one-antigen-mismatched related donors following myeloablative therapy for <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (7), <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (6), <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (8), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (3), or other disorders (6) </plain></SENT>
<SENT sid="1" pm="."><plain>Granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood stem cells were collected from donors in 1 to 3 aphereses </plain></SENT>
<SENT sid="2" pm="."><plain>The apheresis products contained mean counts of 11.3 x 10(8) (range, 3.8-17.2) nucleated cells/kg and 6.7 x 10(6) (range, 1.3-16.7) CD34+ cells/kg </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host-disease</z:e> (GVHD) prophylaxis consisted of <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> plus <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, or FK506 plus <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received G-CSF following their transplant </plain></SENT>
<SENT sid="5" pm="."><plain>Although 1 patient died of <z:hpo ids='HP_0002090'>pneumonia</z:hpo> 6 days after transplantation, the others demonstrated rapid engraftment </plain></SENT>
<SENT sid="6" pm="."><plain>Median days to recovery to 500/microliter neutrophils and 20,000/microliter platelets were 13 (range, 8-21) and 14 (range, 1-23) days, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>The incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD grade II-IV was 33%; <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD developed in 57% of the assessable patients </plain></SENT>
<SENT sid="8" pm="."><plain>There were no episodes of graft failure or rejection </plain></SENT>
<SENT sid="9" pm="."><plain>Nineteen patients (63%) were alive and in complete remission from 147 to 839 days following their transplant (median follow-up of 560 days) </plain></SENT>
<SENT sid="10" pm="."><plain>Further follow-up study will be required to assess the incidence of <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD and graft-versus-<z:hpo ids='HP_0001909'>leukemia</z:hpo> (GVL) effects </plain></SENT>
</text></document>